Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Page values for "Indomethacin"

From Pharmacopedia
More actions

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringIndomethacin
brandStringIndocin (oral, IV, suppository), Tivorbex (low-dose), Indo-Lemmon
structureFile
classesList of String, delimiter: ,[[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID potent non-selective)]] [[:Category:Analgesics|Analgesic]]
mechanismString
usesString'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"'
starting_doseStringAcute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses
preparationsStringCapsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure)
fda_maxString200 mg/day (typical adult oral)
pill_idText
routesList of String, delimiter: ,Oral rectal intravenous (PDA closure only)
onsetString30-60 minutes (oral); rapid relief in acute gout
durationString4-6 hours (IR); 24 hours (ER)
halflifeString4-5 hours'"`UNIQ--ref-00000026-QINU`"'
bioavailabilityString~100% (oral)'"`UNIQ--ref-00000027-QINU`"'
pregnancyStringAvoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks (risk of premature ductus arteriosus closure, which is paradoxically the basis of the neonatal PDA-closure indication)'"`UNIQ--ref-00000028-QINU`"'
legalString[[USLegal:Prescription only|Rx-only]] in US